Evidence & Research Status
New Phase 3a data on cagrilintide semaglutide combination research — published in the New England Journal of Medicine — is drawing significant attention across the peptide research community this…
Evidence Level reflects the general state of published research for this compound category and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use.
New Phase 3a data on cagrilintide semaglutide combination research — published in the New England Journal of Medicine — is drawing significant attention across the peptide research community this month. The REDEFINE-1 trial, presented at the European Congress on Obesity in May 2026, evaluated a fixed-dose combination researchers have nicknamed CagriSema, pairing cagrilintide (a long-acting amylin analog) with semaglutide (a GLP-1 receptor agonist) in adults with overweight or obesity.
Key Takeaways
- REDEFINE-1 examined a combined cagrilintide/semaglutide protocol in a defined trial population.
- Researchers observed weight-related outcomes exceeding those typically reported for semaglutide alone.
- Secondary findings point to additional metabolic markers worth further study.
- Regulatory status remains investigational; this combination is not an approved medication.
Competitive & Market Status
Last reviewed: August 14, 2026
Trial Design and Population
REDEFINE-1 randomized 3,417 adults without type 2 diabetes to one of four arms: cagrilintide 2.4 mg plus semaglutide 2.4 mg (once weekly), cagrilintide alone, semaglutide alone, or placebo. The 68-week trial measured body weight change as its primary endpoint, alongside a battery of cardiometabolic secondary measures. This head-to-head-plus-placebo design lets researchers isolate whether the combination outperforms either compound individually — a question earlier single-arm cagrilintide or semaglutide studies could not answer on their own.
What Researchers Observed
At week 68, the combination arm averaged 20.4% mean body weight reduction, compared with 14.9% for semaglutide alone, 11.5% for cagrilintide alone, and 3% for placebo. Sixty percent of participants in the combination arm achieved at least 20% weight loss, and 23% reached 30% or more — findings that align with a broader trend across GLP-1 and amylin-analog research toward greater efficacy from receptor-pathway combinations.
| Arm | Mean Weight Change (Week 68) |
|---|---|
| Cagrilintide + Semaglutide | -20.4% |
| Semaglutide alone | -14.9% |
| Cagrilintide alone | -11.5% |
| Placebo | -3.0% |
Source: Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity, PubMed; trial summary via American College of Cardiology.
Secondary Findings
Beyond weight change, investigators reported improvements in systolic blood pressure, waist circumference, and lipid levels in the combination arm. Among participants who entered the trial with prediabetes, 88% returned to normoglycemic status by week 68 — a finding researchers are flagging as relevant to the broader metabolic-health literature on amylin/GLP-1 co-agonism, independent of the weight-loss topline.
Regulatory Status
Novo Nordisk submitted the cagrilintide-semaglutide combination to the FDA in December 2025, based on pooled REDEFINE-1 and REDEFINE-2 data. A regulatory decision is anticipated in late 2026. It’s worth noting that a related trial, REDEFINE-4, found the combination achieved 23% weight loss but did not meet its noninferiority threshold against tirzepatide — a reminder that cross-trial comparisons of GLP-1-class research compounds should be read cautiously given differing populations, durations, and endpoints.
Open Questions for Researchers
Several questions remain active in the literature: how durable is the combination’s effect beyond 68 weeks; how does the amylin-analog component of cagrilintide semaglutide co-administration influence gastrointestinal tolerability relative to either compound alone; and how do the observed glycemic and blood-pressure effects hold up in populations with existing type 2 diabetes, which REDEFINE-1 excluded by design. Researchers evaluating cagrilintide or semaglutide independently should treat combination-arm data as directional rather than a substitute for compound-specific trial results.
All compounds referenced in this article are available for research use only. This article is provided for informational and educational purposes. No therapeutic claims are made or implied.
Update — August 4, 2026
Novo Nordisk’s August 4 second-quarter earnings reinforced the differentiation question raised by REDEFINE 4 above: adjusted operating profit rose 11% and the company raised its full-year outlook, yet shares fell partly on CagriSema’s underwhelming head-to-head showing against tirzepatide. Novo says additional CagriSema development, including higher-dose studies, is still planned. Researchers should treat “similar weight loss” between two GLP-1-class compounds as a starting point for comparison, not proof of clinical equivalence — glucose control, tolerability, discontinuation, and dosing complexity can all differ even when headline weight-loss numbers are close. Source: Novo Nordisk Q2 2026 earnings coverage.